Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.

Zhang C, Kutyifa V, Moss AJ, McNitt S, Zareba W, Kaufman ES.

J Cardiovasc Electrophysiol. 2015 Oct;26(10):1039-44. doi: 10.1111/jce.12739. Epub 2015 Aug 6.

2.

Regulatory action and moderate decrease in methylphenidate use among ADHD diagnosed patients aged five and under in Korea.

Shin JY, Lee SH, Shin SM, Shin HN, Park BJ.

Regul Toxicol Pharmacol. 2015 Jul;72(2):244-8. doi: 10.1016/j.yrtph.2015.04.022. Epub 2015 May 6.

PMID:
25957571
3.

Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?

Rohatgi RK, Bos JM, Ackerman MJ.

Heart Rhythm. 2015 Aug;12(8):1807-12. doi: 10.1016/j.hrthm.2015.04.043. Epub 2015 May 5.

4.

Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?

Antel J, Albayrak Ö, Heusch G, Banaschewski T, Hebebrand J.

Eur Arch Psychiatry Clin Neurosci. 2015 Apr;265(3):233-47. doi: 10.1007/s00406-014-0522-8. Epub 2014 Aug 23. Review.

PMID:
25149468
5.

[Cardiovascular risk assessment for the use of ADHD drugs in children].

Berg A, Bråtane E, Odland HH, Brudvik C, Rosland B, Hirth A.

Tidsskr Nor Laegeforen. 2014 Apr 8;134(7):710-4. doi: 10.4045/tidsskr.13.0565. eCollection 2014 Apr 8. Review. Norwegian.

6.

Stimulants for kids with ADHD--how to proceed safely.

Ken Mehta S, Jacobs I.

J Fam Pract. 2014 Feb;63(2):E1-5.

PMID:
24527478
7.

Strategies for the prescription of psychotropic drugs with black box warnings.

Stevens JR, Jarrahzadeh T, Brendel RW, Stern TA.

Psychosomatics. 2014 Mar-Apr;55(2):123-33. doi: 10.1016/j.psym.2013.08.009. Epub 2013 Dec 19. Review.

PMID:
24360525
8.

[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].

Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.

Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3. French.

PMID:
24309201
9.

Management of a hyperactive teen and cardiac safety.

Sowinski H, Karpawich PP.

Pediatr Clin North Am. 2014 Feb;61(1):81-90. doi: 10.1016/j.pcl.2013.09.021. Epub 2013 Oct 30. Review.

PMID:
24267459
10.

Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.

Winterstein AG.

Curr Psychiatry Rep. 2013 Aug;15(8):379. doi: 10.1007/s11920-013-0379-y. Review.

PMID:
23913135
11.

Drugs for attention deficit-hyperactivity disorder do not increase the mid-term risk of sudden death in children: a meta-analysis of observational studies.

Mazza M, D'Ascenzo F, Davico C, Biondi-Zoccai G, Frati G, Romagnoli E, Bassi B, Janiri L, Moretti C, Gaita F.

Int J Cardiol. 2013 Oct 9;168(4):4320-1. doi: 10.1016/j.ijcard.2013.04.169. Epub 2013 May 11. No abstract available.

12.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
13.

Survey of United States child and adolescent psychiatrists' cardiac screening practices prior to starting patients on stimulants.

Leslie LK, Rodday AM, Saunders TS, Cohen JT, Wong JB, Sheldrick RC, Parsons SK.

J Child Adolesc Psychopharmacol. 2012 Oct;22(5):375-84. doi: 10.1089/cap.2011.0141.

14.

[Safety of drugs to treat attention deficit disorder with hyperactivity].

Péluchon R.

Soins Pediatr Pueric. 2012 Sep-Oct;(268):9. French. No abstract available.

PMID:
23074795
15.

Diagnosis and management of sudden death in children.

Fish FA, Kannankeril PJ.

Curr Opin Pediatr. 2012 Oct;24(5):592-602. doi: 10.1097/MOP.0b013e328357a7c3. Review.

PMID:
22954955
16.

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.

Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M.

BMJ. 2012 Jul 18;345:e4627. doi: 10.1136/bmj.e4627.

17.

Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Westover AN, Halm EA.

BMC Cardiovasc Disord. 2012 Jun 9;12:41. doi: 10.1186/1471-2261-12-41. Review.

18.

Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents.

Leslie LK, Cohen JT, Newburger JW, Alexander ME, Wong JB, Sherwin ED, Rodday AM, Parsons SK, Triedman JK.

Circulation. 2012 May 29;125(21):2621-9. doi: 10.1161/CIRCULATIONAHA.111.087940. Epub 2012 May 3.

19.

Cardiac screening prior to stimulant treatment of ADHD: a survey of US-based pediatricians.

Leslie LK, Rodday AM, Saunders TS, Cohen JT, Wong JB, Parsons SK.

Pediatrics. 2012 Feb;129(2):222-30. doi: 10.1542/peds.2011-1574. Epub 2012 Jan 16.

20.

Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment.

Nahshoni E, Golubchik P, Glazer J, Sever J, Strasberg B, Imbar S, Shoval G, Weizman A, Zalsman G.

Eur Child Adolesc Psychiatry. 2012 Feb;21(2):75-8. doi: 10.1007/s00787-011-0233-x. Epub 2011 Dec 11.

PMID:
22160611

Supplemental Content

Loading ...
Support Center